Versor Investments LP Makes New Investment in Privia Health Group, Inc. (NASDAQ:PRVA)

Versor Investments LP bought a new position in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 36,900 shares of the company's stock, valued at approximately $721,000.

Several other large investors have also made changes to their positions in the company. Nordea Investment Management AB boosted its holdings in shares of Privia Health Group by 33.1% in the 4th quarter. Nordea Investment Management AB now owns 349,773 shares of the company's stock worth $6,953,000 after acquiring an additional 86,910 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Privia Health Group by 402.9% in the third quarter. Victory Capital Management Inc. now owns 179,049 shares of the company's stock worth $3,260,000 after purchasing an additional 143,446 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Privia Health Group by 2.2% during the third quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company's stock worth $23,092,000 after purchasing an additional 28,480 shares during the last quarter. Barclays PLC grew its holdings in shares of Privia Health Group by 240.3% during the third quarter. Barclays PLC now owns 224,018 shares of the company's stock worth $4,079,000 after purchasing an additional 158,188 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Privia Health Group by 8.4% in the third quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company's stock valued at $3,430,000 after buying an additional 14,641 shares in the last quarter. Institutional investors own 94.48% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PRVA. JMP Securities reissued a "market outperform" rating and set a $26.00 price objective on shares of Privia Health Group in a report on Friday, February 14th. Macquarie began coverage on shares of Privia Health Group in a research note on Monday, December 16th. They set an "outperform" rating and a $25.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Friday, November 29th. Needham & Company LLC increased their price objective on Privia Health Group from $25.00 to $30.00 and gave the company a "buy" rating in a research report on Friday. Finally, Barclays boosted their price objective on Privia Health Group from $19.00 to $21.00 and gave the stock an "equal weight" rating in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $26.47.

Privia Health Group Trading Up 2.7 %

Shares of Privia Health Group stock traded up $0.67 during trading on Tuesday, reaching $25.63. The stock had a trading volume of 613,387 shares, compared to its average volume of 750,979. The company has a market capitalization of $3.08 billion, a price-to-earnings ratio of 256.44, a P/E/G ratio of 3.47 and a beta of 0.87. The stock has a fifty day moving average price of $22.50 and a two-hundred day moving average price of $20.64. Privia Health Group, Inc. has a 52 week low of $15.92 and a 52 week high of $26.04.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.